| Quarterly Financials | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 463 | 457 | 532 | 472 | 486 | 459 | 441 | 450 | 508 | 558 | 463 | 543 | 562 | 388 | 418 |
| Expenses | 385 | 371 | 441 | 385 | 405 | 374 | 352 | 353 | 388 | 459 | 364 | 409 | 418 | 293 | 344 |
| EBITDA | 78 | 86 | 91 | 87 | 81 | 85 | 89 | 97 | 120 | 99 | 98 | 134 | 144 | 95 | 74 |
| Operating Profit % | 16 % | 19 % | 17 % | 18 % | 16 % | 19 % | 20 % | 21 % | 23 % | 17 % | 20 % | 24 % | 26 % | 24 % | 18 % |
| Depreciation | 14 | 14 | 17 | 16 | 16 | 17 | 18 | 19 | 19 | 20 | 21 | 23 | 23 | 23 | 25 |
| Interest | 5 | 4 | 6 | 5 | 6 | 4 | 4 | 5 | 5 | 5 | 6 | 10 | 7 | 7 | 11 |
| Profit Before Tax | 60 | 68 | 69 | 65 | 59 | 64 | 67 | 74 | 96 | 74 | 72 | 101 | 115 | 65 | 39 |
| Tax | 11 | 16 | 18 | 17 | 16 | 17 | 15 | 21 | 31 | 18 | 17 | 27 | 26 | 16 | 11 |
| Net Profit | 49 | 52 | 51 | 48 | 43 | 47 | 52 | 53 | 65 | 56 | 55 | 74 | 88 | 50 | 28 |
| EPS in ₹ | 5.39 | 5.72 | 5.64 | 5.26 | 4.73 | 5.20 | 5.72 | 5.82 | 7.20 | 6.12 | 6.03 | 8.16 | 9.75 | 5.46 | 3.08 |
Aarti Pharma Labs
Aarti Pharma Labs
710.45
+31.55
(4.65%)
Market Cap
₹6,439.61 Cr
PE Ratio
26.95
Volume
9,16,886.00
Day High - Low
₹730.75 - ₹681.25
52W High-Low
₹971.00 - ₹557.05
Key Fundamentals
Market Cap
6,439.61 Cr
EPS
30.06
PB Ratio
3.16
Book Value
225.73
EBITDA
474.50
Dividend Yield
0.70 %
Industry
Healthcare Sector
Pharmaceuticals ROE Growth %
-
Debt to Equity
0.19
Actual
Company News
View All News
Aarti Pharmalabs achieved standalone revenue of INR 417 crores in Q2FY26 versus INR 377 crores year-on-year, though EBITDA declined to INR 75 crores from INR 85 crores due to margin pressures in API business and forex losses of INR 7.4 crores. The company inaugurated its Atali plant in September and revised full-year EBITDA growth guidance to 8-12%, with CDMO business expected to exceed earlier projected 30-40% growth driven by 39 commercial projects across 21 customers.
Aarti Pharmalabs Reports Q2 FY26 Results with Revenue Growth but Margin PressureNov 11, 2025
Aarti Pharmalabs Limited reported quarterly results showing operational revenue of INR 4,183 million in Q2 FY26, up 8.3% quarter-on-quarter but down 8.7% year-on-year. EBITDA margin declined to 17.86% from 24.68% in the previous quarter and 20.46% in the same quarter last year. PAT dropped to INR 279 million from INR 495 million in Q2 FY25, with PAT margin falling to 6.67%. The company was negatively impacted by a forex loss of INR 7.4 crores in Q2 FY26. For the half-year period, operational revenue was INR 8,045 million with EBITDA margin of 21.14% and PAT of INR 775 million. The Xanthine derivatives segment operated at incremental capacity with better margins from beverage customers, while the API business witnessed margin pressure due to sales mix skewed toward lower margin products. The company operationalized its Atali Greenfield site in Q2 FY26 and expects CDMO business to meet growth expectations for FY26.
Aarti Pharmalabs Reports Strong Growth in Quarterly Results with Revenue Rising to Rs 417.29 Crores
Nov 09, 2025
Nov 09, 2025Aarti Pharmalabs Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2025. The pharmaceutical company reported standalone revenue from operations of Rs 417.29 crores for the quarter, compared to Rs 375.31 crores in the previous quarter. Net profit for the quarter stood at Rs 30.85 crores versus Rs 21.23 crores in the prior quarter. For the half-year period, revenue reached Rs 792.60 crores against Rs 770.78 crores previously, with net profit of Rs 52.08 crores compared to Rs 47.82 crores. The company operates solely in the pharmaceuticals segment and has subsidiaries including Aarti USA Inc and Aarti Pharmachem Ltd, along with a joint venture with Ganesh Polychem Limited effective from April 1, 2025. The Board of Directors approved these results in their meeting held on November 9, 2025.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,804.90 | #1 4,33,055.97 | 40.68 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 75.42 | |
6,510.00 | 1,72,820.05 | 69.05 | 9,712.00 | 18.67 | 2,191 | 35.10 | 51.73 | |
3,755.80 | 1,27,113.34 | 58.80 | 11,539.40 | 6.99 | 1,911 | 30.46 | 58.02 | |
1,523.80 | 1,23,085.57 | 22.73 | 28,409.50 | 7.12 | 5,291 | 3.71 | 48.15 | |
1,248.00 | 1,04,159.80 | #1 18.15 | 33,741.20 | 16.73 | 5,725 | -0.38 | 53.26 | |
940.55 | 94,641.34 | 18.56 | 23,511.00 | 18.55 | 4,615 | 34.60 | 42.59 | |
2,071.60 | 94,621.27 | 21.34 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 63.49 | |
2,258.90 | 93,238.02 | 52.05 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 39.74 | |
1,227.40 | 71,287.59 | 20.70 | 32,345.60 | 9.43 | 3,484 | 3.81 | 65.66 | |
5,773.00 | 69,024.87 | 28.29 | 13,458.30 | 3.70 | 2,216 | 10.98 | 63.75 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
14.41 %
Net Income Growth
25.59 %
Cash Flow Change
53.25 %
ROE
10.94 %
ROCE
2.38 %
EBITDA Margin (Avg.)
6.08 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 0 | 2,040 | 2,244 | 2,582 | 2,906 |
| Fixed Assets | 0 | 782 | 926 | 1,033 | 1,137 |
| Current Assets | 0 | 1,028 | 1,163 | 1,346 | 1,322 |
| Capital Work in Progress | 0 | 187 | 102 | 137 | 374 |
| Investments | 0 | 32 | 87 | 107 | 77 |
| Other Assets | 0 | 1,038 | 1,130 | 1,305 | 1,319 |
| Total Liabilities | 0 | 2,040 | 2,244 | 2,582 | 2,906 |
| Current Liabilities | 0 | 581 | 601 | 694 | 657 |
| Non Current Liabilities | 0 | 73 | 85 | 131 | 259 |
| Total Equity | 0 | 1,387 | 1,559 | 1,757 | 1,990 |
| Reserve & Surplus | 0 | 1,341 | 1,513 | 1,712 | 1,945 |
| Share Capital | 0 | 0 | 45 | 45 | 45 |
Cash Flow
| Cash Flow | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 0 | 78 | -71 | 12 | -17 |
| Investing Activities | 0 | -139 | -158 | -215 | -414 |
| Operating Activities | 0 | -44 | 250 | 216 | 332 |
| Financing Activities | 0 | 260 | -164 | 10 | 65 |
Share Holding
| % Holding | Jan 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 44.16 % | 45.98 % | 45.98 % | 46.30 % | 46.46 % | 46.46 % | 46.46 % | 46.10 % | 44.66 % | 44.29 % | 43.72 % | 42.88 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 8.16 % | 8.32 % | 7.06 % | 7.38 % | 8.64 % | 7.36 % | 7.35 % | 8.02 % |
| DIIs | 14.73 % | 13.70 % | 10.66 % | 10.51 % | 9.91 % | 9.97 % | 11.47 % | 11.35 % | 10.36 % | 7.53 % | 7.80 % | 6.96 % |
| Government | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % |
| Public / Retail | 24.66 % | 28.35 % | 30.23 % | 29.13 % | 29.74 % | 29.71 % | 29.57 % | 29.45 % | 30.39 % | 34.10 % | 34.43 % | 35.39 % |
| Others | 16.44 % | 11.96 % | 13.12 % | 14.04 % | 5.72 % | 5.52 % | 5.43 % | 5.71 % | 5.94 % | 6.71 % | 6.69 % | 6.74 % |
| No of Share Holders | 3,05,456 | 2,76,664 | 2,58,236 | 2,26,286 | 2,15,796 | 2,04,122 | 1,89,012 | 1,85,436 | 1,85,111 | 1,96,314 | 1,87,039 | 1,90,655 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2 | 3 | 5 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.46 | 0.4 | 0.74 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 19 Feb 2024 |  Dividend | ₹ 2.00 /share | 16 Feb 2024 | 550.70 | 536.20 |
| 31 Jul 2024 | Dividend | ₹ 1.00 /share | 31 Jul 2024 | 502.45 | 614.95 |
| 07 Aug 2024 |  Annual General Meeting | NA | 07 Aug 2024 | 608.50 | 595.85 |
| 28 Oct 2024 |  Quarterly Result Announcement | NA | 28 Oct 2024 | 610.40 | 605.40 |
| 05 Feb 2025 | Quarterly Result Announcement | NA | 05 Feb 2025 | 599.00 | 623.00 |
| 14 Feb 2025 | Dividend | ₹ 2.50 /share | 14 Feb 2025 | 623.00 | 733.45 |
| 10 May 2025 | Quarterly Result Announcement | NA | 10 May 2025 | 754.25 | 767.35 |
| 12 Aug 2025 | Quarterly Result Announcement | NA | 12 Aug 2025 | 911.20 | 857.15 |
| 15 Sept 2025 | Dividend | ₹ 2.50 /share | 15 Sept 2025 | 767.35 | 926.55 |
| 22 Sept 2025 | Annual General Meeting | NA | 22 Sept 2025 | 845.95 | 930.20 |
| 09 Nov 2025 | Quarterly Result Announcement | NA | 09 Nov 2025 | 832.20 | 864.95 |
Announcements
Announcement under Regulation 30 (LODR)-Earnings Call Transcript9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 11, 2025
Nov 11, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 11, 2025
Nov 11, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 11, 2025
Nov 11, 2025Financial Results For Quarter And Half Year Ended September 30 2025Nov 09, 2025
Nov 09, 2025Board Meeting Outcome for Board Meeting Outcome For Financial Results For The Quarter And Half Year Ended September 30 2025.Nov 09, 2025
Nov 09, 2025Board Meeting Outcome for Board Meeting Outcome For Financial Results For The Quarter And Half Year Ended September 30 2025.Nov 09, 2025
Nov 09, 2025Announcement under Regulation 30 (LODR)-Change in ManagementNov 09, 2025
Nov 09, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 04, 2025
Nov 04, 2025Board Meeting Intimation for Board Meeting Intimation For Approval Of Unaudited Standalone And Consolidated Financial Results For The Second Quarter And Half Year Ended September 30 2025Oct 27, 2025
Oct 27, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSOct 13, 2025
Oct 13, 2025Ex-Parte Ad-Interim Injunction Order Regarding Pharmaceutical Drug Product Containing Ruxolitinib And/Or Ruxolitinib Phosphate APIOct 08, 2025
Oct 08, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
Oct 07, 2025Closure of Trading WindowSep 25, 2025
Sep 25, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 24, 2025
Sep 24, 2025Announcement under Regulation 30 (LODR)-Investor PresentationSep 23, 2025
Sep 23, 2025Announcement under Regulation 30 (LODR)-Change in ManagementSep 23, 2025
Sep 23, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 23, 2025
Sep 23, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 22, 2025
Sep 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 18, 2025
Sep 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 18, 2025
Sep 18, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 03, 2025
Sep 03, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 30, 2025
Aug 30, 2025Reg. 34 (1) Annual Report.Aug 29, 2025
Aug 29, 2025Business Responsibility and Sustainability Reporting (BRSR)Aug 29, 2025
Aug 29, 2025Notice Of 6Th Annual General MeetingAug 29, 2025
Aug 29, 2025Intimation Regarding 100 Days Campaign - Saksham NiveshakAug 21, 2025
Aug 21, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 20, 2025
Aug 20, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 20, 2025
Aug 20, 2025Record Date For Final Dividend For FY 2024-25Aug 19, 2025
Aug 19, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 12, 2025
Aug 12, 2025Financial Results For Quarter Ended June 30 2025Aug 12, 2025
Aug 12, 2025Appointment Of Secretarial AuditorAug 12, 2025
Aug 12, 2025Board Meeting Outcome for Outcome Of Board Meeting For Approval Of Unaudited Financial Results With Limited Review Report For The Quarter Ended June 30 2025Aug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 05, 2025
Aug 05, 2025Board Meeting Intimation for Board Meeting Intimation For Unaudited Financial Results For The Quarter Ended June 30 2025.Aug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Credit RatingJul 17, 2025
Jul 17, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 09, 2025
Jul 09, 2025Closure of Trading WindowJun 25, 2025
Jun 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 18, 2025
Jun 18, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 16, 2025
May 16, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 12, 2025
May 12, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 12, 2025
May 12, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 12, 2025
May 12, 2025Grant Of Options Under PSOP Scheme 2023May 10, 2025
May 10, 2025Mutual Fund Holdings
Taurus Flexi Cap Fund Direct - Growth 
Samco Multi Cap Fund Direct-Growth 
Motilal Oswal Nifty Microcap 250 Index Fund Direct - Growth 
Groww Nifty Total Market Index Fund Direct - Growth 
Angel One Nifty Total Market Index Fund Direct - Growth 
Bandhan BSE Healthcare Index Fund Direct-Growth 
Mirae Asset Nifty Total Market Index Fund Direct-Growth 
Quant Business Cycle Fund Direct-Growth 
HDFC Multi Cap Fund Direct - Growth 
Unifi Flexi Cap Fund Direct-Growth 
Union Active Momentum Fund Direct-Growth Technical Indicators
RSI(14)
Neutral 25.43
ATR(14)
Less Volatile 26.58
STOCH(9,6)
Oversold 8.07
STOCH RSI(14)
Oversold 1.23
MACD(12,26)
Bearish -9.13
ADX(14)
Strong Trend 37.87
UO(9)
Bearish 38.19
ROC(12)
Downtrend And Accelerating -21.51
WillR(14)
Oversold -96.86
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
